Intra-Cellular Therapies (ITCI) Q3 2024 earnings summary

Executive summary

• Caplyta net product sales reached $175.2 million in Q3 2024, up 39% year-over-year, driven by strong prescription growth in bipolar depression and schizophrenia.

• 2024 full-year net sales guidance was raised to $665 million–$685 million, reflecting continued momentum and confidence in future growth.

• The company completed a $575 million public offering in April 2024, strengthening its cash position to over $1 billion.

• Caplyta's efficacy and safety profile in mood disorders supports a projected $5 billion opportunity within 10 years.

• The company is advancing a broad pipeline, including lumateperone long-acting injectable, ITI-1284 for GAD and Alzheimer's-related psychosis, and ITI-1549 for mood and anxiety disorders.

Financial highlights

• Q3 2024 net product sales were $175.2 million, up 39% year-over-year and 9% sequentially from Q2 2024.

• SG&A expenses for Q3 were $132.1 million, up from $105.2 million in Q3 2023, mainly due to sales force expansion and increased marketing.

• R&D expenses rose to $66.8 million from $41.6 million year-over-year, reflecting increased clinical activity.

• Cash and investments totaled $1 billion as of September 30, 2024, up from $499.7 million at year-end 2023.

• Net loss for Q3 2024 was $26.3 million, compared to $24.3 million in Q3 2023.

Outlook and guidance

• Net product sales guidance for 2024 increased to $665 million–$685 million, with gross-to-net expected to remain in the mid-30% range.

• Full-year SG&A expense guidance narrowed to $490 million–$510 million; R&D guidance set at $220 million–$230 million.

• Continued strong prescription demand and further sales force expansion expected to drive growth in Q4 and 2025.

• Anticipates submitting a supplemental NDA for lumateperone in MDD in Q4 2024 and reporting topline results from a schizophrenia relapse prevention study.

• Ongoing expansion of clinical programs, including pediatric and long-acting injectable formulations.